Articles with public access mandates - Jaap VerweijLearn more
Not available anywhere: 5
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
RD Baird, J Kitzen, PA Clarke, A Planting, S Reade, A Reid, L Welsh, ...
Molecular cancer therapeutics 8 (6), 1430-1437, 2009
Mandates: Cancer Research UK
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
N van Erp, H Gelderblom, M Van Glabbeke, A Van Oosterom, J Verweij, ...
Clinical Cancer Research 14 (24), 8308-8313, 2008
Mandates: US National Institutes of Health
A phase I study of an MPS1 inhibitor (BAY 1217389) in combination with paclitaxel using a novel randomized continual reassessment method for dose escalation
F Atrafi, O Boix, V Subbiah, JR Diamond, SP Chawla, AW Tolcher, ...
Clinical Cancer Research 27 (23), 6366-6375, 2021
Mandates: US Department of Defense
Dose–response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study
V Moreno García, D Olmos, C Gomez-Roca, PA Cassier, ...
Clinical cancer research 20 (22), 5663-5671, 2014
Mandates: Cancer Research UK, National Institute for Health Research, UK
Treatment options for metastatic gastrointestinal stromal tumors to the liver: a review
HA Lillemoe, KW Brudvik, JN Vauthey
Seminars in liver disease 39 (03), 395-402, 2019
Mandates: US National Institutes of Health
Available somewhere: 32
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
The lancet oncology 15 (4), 415-423, 2014
Mandates: Canadian Cancer Society, Cancer Research UK, National Institute for Health …
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ...
Cancer research 69 (13), 5383-5391, 2009
Mandates: US National Institutes of Health
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
RD Issels, LH Lindner, J Verweij, P Wust, P Reichardt, BC Schem, ...
The lancet oncology 11 (6), 561-570, 2010
Mandates: US National Institutes of Health
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
PJ Woll, P Reichardt, A Le Cesne, S Bonvalot, A Azzarelli, HJ Hoekstra, ...
The lancet oncology 13 (10), 1045-1054, 2012
Mandates: US National Institutes of Health, Cancer Research UK
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation …
P Lorigan, J Verweij, Z Papai, S Rodenhuis, A Le Cesne, MG Leahy, ...
Journal of Clinical Oncology 25 (21), 3144-3150, 2007
Mandates: Cancer Research UK
Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 …
RD Issels, LH Lindner, J Verweij, R Wessalowski, P Reichardt, P Wust, ...
JAMA oncology 4 (4), 483-492, 2018
Mandates: US National Institutes of Health, Helmholtz Association
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
MTM Van Jaarsveld, J Helleman, AWM Boersma, PF Van Kuijk, ...
Oncogene 32 (36), 4284-4293, 2013
Mandates: Dutch Cancer Society
Individual patient data analysis to assess modifications to the RECIST criteria
J Bogaerts, R Ford, D Sargent, LH Schwartz, L Rubinstein, D Lacombe, ...
European journal of cancer 45 (2), 248-260, 2009
Mandates: US National Institutes of Health
Pharmacogenetic pathway analysis of docetaxel elimination
SD Baker, J Verweij, GA Cusatis, RH Van Schaik, S Marsh, SJ Orwick, ...
Clinical Pharmacology & Therapeutics 85 (2), 155-163, 2009
Mandates: US National Institutes of Health
Interaction of Cisplatin with the human organic cation transporter 2
KK Filipski, WJ Loos, J Verweij, A Sparreboom
Clinical Cancer Research 14 (12), 3875-3880, 2008
Mandates: US National Institutes of Health
Determining the optimal dose in the development of anticancer agents
RHJ Mathijssen, A Sparreboom, J Verweij
Nature reviews Clinical oncology 11 (5), 272-281, 2014
Mandates: US National Institutes of Health
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
GD Demetri, CR Garrett, P Schöffski, MH Shah, J Verweij, S Leyvraz, ...
Clinical Cancer Research 18 (11), 3170-3179, 2012
Mandates: US National Institutes of Health, Government of Spain
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the …
A Le Cesne, M Van Glabbeke, J Verweij, PG Casali, M Findlay, ...
Journal of clinical oncology 27 (24), 3969-3974, 2009
Mandates: US National Institutes of Health
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents–dose …
S Postel-Vinay, L Collette, X Paoletti, E Rizzo, C Massard, D Olmos, ...
European Journal of Cancer 50 (12), 2040-2049, 2014
Mandates: Cancer Research UK, National Institute for Health Research, UK
CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
AJM de Graan, L Elens, JA Sprowl, A Sparreboom, LE Friberg, ...
Clinical Cancer Research 19 (12), 3316-3324, 2013
Mandates: US National Institutes of Health, Dutch Cancer Society
Publication and funding information is determined automatically by a computer program